Effectiveness of PGx Testing

NAActive, not recruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

November 15, 2019

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2027

Conditions
Polypharmacy
Interventions
DIAGNOSTIC_TEST

Pharmacogenomic test

The RightMed test is an end-to-end solution which includes sample collection, PGx testing services, data analysis, and clinical interpretation that helps prescribers select treatments based on evidence-driven predictions of patient drug response and tolerance. Genetic components of an individual's drug response are well established and often included on FDA medication labels. The RightMed test has incorporated existing evidence to classify the risk and likelihood of an antidepressant working for different patients. Patient results for each medication can fall into one of three categories: 1) Green - use as directed; 2) Yellow - use with caution; and 3) Red - adjust dose or choose alternative mediation.

Trial Locations (1)

80011

Central Support Services, Aurora

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

OneOme, LLC

INDUSTRY

lead

Kaiser Permanente

OTHER